Earnings

Does Infinity Pharmaceuticals, Inc. (INFI) Present Much Upside ?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value of 80.23M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For INFI, the company currently has 66.71 million of cash on the books, which is offset by 456,000 in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 90.85 million in total assets, balanced by 31.94 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Infinity Pharmaceuticals, Inc. (INFI) saw -9.71 million in free cash flow last quarter, representing a quarterly net change in cash of -9.23 million. Perhaps most importantly where cash movements are concerned, the company saw about -9.71 million in net operating cash flow.



Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. That represents a quarterly year/year change in revenues of -1.00 in sequential terms, the INFI saw sales decline by 0.00.

But what about the bottom line? After all, that’s what really matters in the end. Infinity Pharmaceuticals, Inc. (INFI) is intriguing when broken down to its core data. The cost of selling goods last quarter was 692,000, yielding a gross basic income of -692,000 . For shareholders, given the total diluted outstanding shares of 50.46 million, this means overall earnings per share of -0.34. Note, this compares with a consensus analyst forecast of -0.21 in earnings per share for its next fiscal quarterly report.




Is Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.93 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Infinity Pharmaceuticals, Inc..

Previous ArticleNext Article

Related Post

Accuray Incorporated (ARAY) and Wright Medical Gro... Wright Medical Group N.V. (NASDAQ:WMGI), on the other hand, is up 2.79% year to date as of 01/02/2018. It currently trades at $22.82 and has returned ...
Choosing Between Ocular Therapeutix, Inc. (OCUL) a... Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares are up more than 19.33% this year and recently decreased -14.22% or -$0.88 to settle at $5.31. Immunomed...
Comparing PDL BioPharma, Inc. (PDLI) and Marinus P... PDL BioPharma, Inc. (NASDAQ:PDLI) shares are up more than 6.20% this year and recently increased 2.83% or $0.08 to settle at $2.91. Marinus Pharmaceut...
A Side-by-side Analysis of CBL & Associates P... CBL & Associates Properties, Inc (NYSE:CBL) shares are down more than -25.80% this year and recently decreased -15.66% or -$0.78 to settle at $4.2...
A Side-by-side Analysis of Prudential Financial, I... Prudential Financial, Inc. (NYSE:PRU) shares are down more than -7.04% this year and recently decreased -0.90% or -$0.97 to settle at $106.89. Lincoln...